Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Aprile

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 23, 2012
Unplanned presentations of cancer outpatients: a retrospective cohort studyG Aprile, F E Pisa, A Follador, et al.
Anticancer Research|March 26, 2002
Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomasF Puglisi, G Aprile, A M Minisini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 2, 2025
Geriatric Oncology in Italy. Where we are. A CIPOMO (Italian College of Primary Hospital Medical Oncologists)-Gioger (Italian Group of Geriatric Oncology) SurveyS Barni, A Luciani, P Tralongo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)C Pinto, F Di Fabio, E Maiello, et al.
British Journal of Cancer|March 2, 2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancerM Reni, L Pasetto, G Aprile, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 16, 2023
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)P Di Nardo, D Basile, A Siciliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
The Pharmacogenomics Journal|March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancerF Graziano, A Ruzzo, E Giacomini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open|February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE studyC Antoniotti, M Carullo, D Rossini, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 23, 2012
Unplanned presentations of cancer outpatients: a retrospective cohort studyG Aprile, F E Pisa, A Follador, et al.
Anticancer Research|March 26, 2002
Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomasF Puglisi, G Aprile, A M Minisini, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 2, 2025
Geriatric Oncology in Italy. Where we are. A CIPOMO (Italian College of Primary Hospital Medical Oncologists)-Gioger (Italian Group of Geriatric Oncology) SurveyS Barni, A Luciani, P Tralongo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 10, 2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)C Pinto, F Di Fabio, E Maiello, et al.
British Journal of Cancer|March 2, 2006
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancerM Reni, L Pasetto, G Aprile, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 16, 2023
Second-line treatment strategies for RAS wild-type colorectal cancer: A systematic review and Network Meta-analysis (NMA)P Di Nardo, D Basile, A Siciliano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 14, 2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)L Fornaro, S Lonardi, G Masi, et al.
The Pharmacogenomics Journal|March 2, 2016
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancerF Graziano, A Ruzzo, E Giacomini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 9, 2015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosisC Cremolini, M Di Bartolomeo, A Amatu, et al.
ESMO Open|February 5, 2025
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE studyC Antoniotti, M Carullo, D Rossini, et al.
Pageof 6